- Home
- RNA vs EXPO Comparison
RNA vs EXPO Comparison
Compare RNA & EXPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- EXPO
- Stock Information
- Founded
- RNA 2012
- EXPO 1967
- Country
- RNA United States
- EXPO United States
- Employees
- RNA N/A
- EXPO N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- EXPO Professional Services
- Sector
- RNA Health Care
- EXPO Consumer Discretionary
- Exchange
- RNA Nasdaq
- EXPO Nasdaq
- Market Cap
- RNA 4.0B
- EXPO 3.5B
- IPO Year
- RNA 2020
- EXPO 1990
- Fundamental
- Price
- RNA $69.66
- EXPO $65.45
- Analyst Decision
- RNA Buy
- EXPO
- Analyst Count
- RNA 20
- EXPO 0
- Target Price
- RNA $69.26
- EXPO N/A
- AVG Volume (30 Days)
- RNA 7.5M
- EXPO 320.2K
- Earning Date
- RNA 11-07-2025
- EXPO 10-30-2025
- Dividend Yield
- RNA N/A
- EXPO 1.83%
- EPS Growth
- RNA N/A
- EXPO N/A
- EPS
- RNA N/A
- EXPO 1.99
- Revenue
- RNA $10,729,000.00
- EXPO $519,154,000.00
- Revenue This Year
- RNA N/A
- EXPO $4.31
- Revenue Next Year
- RNA $108.26
- EXPO $7.48
- P/E Ratio
- RNA N/A
- EXPO $32.86
- Revenue Growth
- RNA 1.23
- EXPO 2.10
- 52 Week Low
- RNA $21.51
- EXPO $63.81
- 52 Week High
- RNA $70.51
- EXPO $112.75
- Technical
- Relative Strength Index (RSI)
- RNA 79.48
- EXPO 35.96
- Support Level
- RNA $69.65
- EXPO $65.10
- Resistance Level
- RNA $72.05
- EXPO $70.41
- Average True Range (ATR)
- RNA 1.98
- EXPO 1.35
- MACD
- RNA 2.39
- EXPO -0.13
- Stochastic Oscillator
- RNA 90.77
- EXPO 8.32
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About EXPO Exponent Inc.
Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.